You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies
Free

Authors

Citation

Joshi R, Goh J, Joubert W, et al
632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0632

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.